A tense moment broke out at the White House on Thursday when a man suddenly collapsed behind President Donald Trump during an event announcing lower prices for weight-loss drugs.
The man, later identified as a guest of pharmaceutical company Eli Lilly, fainted while standing behind the president’s desk in the Oval Office. Eli Lilly CEO David Ricks was speaking when the guest crumpled to the floor, prompting immediate concern.
“You OK?” Ricks asked as others helped the man lie down. The attendees had reportedly been standing for around 30 minutes before the incident. Trump, who was seated, quickly stood up while staffers and medical personnel attended to the man.
The event was paused for about an hour while the guest received medical attention. According to Reuters, the individual was evaluated by Mehmet Oz, Trump’s administrator for the Centers for Medicare and Medicaid Services, and later declared fine.
Trump Addresses the Scare
When the event resumed, Trump reassured reporters that the man was doing well. “He got a little bit light-headed. You saw he went down. And he’s fine,” Trump said. “They just sent him out. He’s got doctors’ care.”
David Ricks later identified the man as “Gordon,” a guest of Eli Lilly. “He became faint, and if you’ve ever been in the Oval Office, you stand a long time, and it’s warm,” Ricks said. “The White House medical staff did a great job, and he’s doing great.”
Trump’s Big Announcement
Before the interruption, Trump had announced deals with pharmaceutical giants Eli Lilly and Novo Nordisk to reduce the prices of popular GLP-1 weight-loss drugs, including Zepbound and Wegovy. These drugs are known for helping people lose weight but often cost more than $1,000 a month in the United States.
Trump said both companies agreed to offer “drastic discounts” on their most popular medications in exchange for relief from threatened tariffs. “Eli Lilly and Novo Nordisk are committing to offer Zepbound and Wegovy at ‘Most Favored Nation’ rates for American patients,” Trump said.
The new generation of appetite-suppressing GLP-1 agonist drugs, such as Ozempic, Wegovy, and Mounjaro, has become a global phenomenon for their effectiveness in weight loss. However, their high prices have sparked concern over affordability and accessibility.
The announcement represents Trump’s latest effort to frame drug price cuts as part of his economic agenda, a move closely watched by both political observers and healthcare experts. The White House did not release further details about the pricing terms but confirmed ongoing collaboration with pharmaceutical companies.
For additional updates, visit The New York Times coverage of healthcare and policy developments.